OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
6130$24.4058

Shangya Technology Co Ltd

PharmaceuticalsVerified

Shangya Technology Co Ltd has a market price of 24.4 TWD and a market cap of 1,080,920,000 TWD, with a price-to-book ratio of 1.98 and a price-to-tangible-book ratio of 1.98. The company's liquidity is characterized by a current ratio of 3.09 and cash and equivalents of 187,585,000 TWD, indicating a relatively strong short-term liquidity position. However, the company reported negative operating cash flow of -44,153,000 TWD and free cash flow of -117,469,000 TWD, suggesting challenges in generating positive cash flow from operations. Profitability metrics show a return on equity of -0.1399 and a return on assets of -0.0869, indicating a loss-making position. The company's operating income is negative at -84,840,000 TWD, and net income is also negative at -76,310,000 TWD, which is below the industry median for profitability metrics. The debt-to-equity ratio of 0.33 suggests a relatively low level of leverage, which is favorable for financial stability. The company's revenue is derived from multiple segments, including Western medicine trading, solar power generation, real estate leasing, and power IC design, production, and sales. The geographic exposure is primarily within Taiwan, with sales to medical centers, public hospitals, foundation hospitals, and clinics, as well as to Taiwan power companies. The company's revenue concentration is not explicitly detailed, but the diverse business segments suggest a moderate level of diversification. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's capital expenditure of -67,010,000 TWD indicates a reduction in investment, which may affect future growth potential. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, and no significant adjustments have been applied to the valuation metrics. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's business model and financial performance suggest a need for strategic adjustments to improve profitability and cash flow generation.

30-day price · 6130-2.65 (-10.7%)
Low$20.70High$29.05Close$22.15As of21 May, 00:00 UTC
Profile
CompanyShangya Technology Co Ltd
Ticker6130.TWO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Shangya Technology Co Ltd is a Taiwan-based company engaged in the provision of Western medicine products, including nervous system drugs, antineoplastic drugs, and cardiovascular system drugs, and operates in solar power generation, real estate leasing, and power IC design, production, and sales.

Classification. Shangya Technology Co Ltd is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Shangya Technology Co Ltd has a market price of 24.4 TWD and a market cap of 1,080,920,000 TWD, with a price-to-book ratio of 1.98 and a price-to-tangible-book ratio of 1.98. The company's liquidity is characterized by a current ratio of 3.09 and cash and equivalents of 187,585,000 TWD, indicating a relatively strong short-term liquidity position. However, the company reported negative operating cash flow of -44,153,000 TWD and free cash flow of -117,469,000 TWD, suggesting challenges in generating positive cash flow from operations. Profitability metrics show a return on equity of -0.1399 and a return on assets of -0.0869, indicating a loss-making position. The company's operating income is negative at -84,840,000 TWD, and net income is also negative at -76,310,000 TWD, which is below the industry median for profitability metrics. The debt-to-equity ratio of 0.33 suggests a relatively low level of leverage, which is favorable for financial stability. The company's revenue is derived from multiple segments, including Western medicine trading, solar power generation, real estate leasing, and power IC design, production, and sales. The geographic exposure is primarily within Taiwan, with sales to medical centers, public hospitals, foundation hospitals, and clinics, as well as to Taiwan power companies. The company's revenue concentration is not explicitly detailed, but the diverse business segments suggest a moderate level of diversification. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's capital expenditure of -67,010,000 TWD indicates a reduction in investment, which may affect future growth potential. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, and no significant adjustments have been applied to the valuation metrics. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's business model and financial performance suggest a need for strategic adjustments to improve profitability and cash flow generation.
Key takeaways
  • Shangya Technology Co Ltd is a diversified company with operations in pharmaceuticals, solar power, real estate, and power IC design, but it is currently reporting losses.
  • The company's liquidity position is strong, with a current ratio of 3.09 and significant cash and equivalents, but it is generating negative operating and free cash flows.
  • Profitability metrics are negative, with a return on equity of -0.1399 and a return on assets of -0.0869, indicating a need for operational improvements.
  • The company's debt-to-equity ratio is low at 0.33, which is favorable for financial stability.
  • The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
  • The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$154.7M
Gross profit$46.5M
Operating income-$84.8M
Net income-$76.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$44.2M
CapEx-$67.0M
Free cash flow-$117.5M
Total assets$877.8M
Total liabilities$332.3M
Total equity$545.5M
Cash & equivalents$187.6M
Long-term debt$181.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$24.40
Market cap$1.08B
Enterprise value$1.07B
P/E
Reported non-GAAP P/E
EV/Revenue6.9
EV/Op income
EV/OCF
P/B2.0
P/Tangible book2.0
Tangible book$545.5M
Net cash$6.5M
Current ratio3.1
Debt/Equity0.3
ROA-8.7%
ROE-14.0%
Cash conversion58.0%
CapEx/Revenue-43.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric6130Activity
Op margin-54.8%-2.9% medp25 -218.9% · p75 9.6%below median
Net margin-49.3%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin30.0%47.8% medp25 27.6% · p75 68.9%below median
CapEx / revenue-43.3%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity33.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
Last actual EPS2.88 TWD
Last actual revenue223,536,000 TWD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 18:43 UTC#e20478c1
Market quoteclose TWD 24.40 · shares 0.04B diluted
no public URL
2026-05-03 13:20 UTC#cfee355d
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 13:21 UTCJob: 224bb1b5